Fit-for-Purpose Ki-67 Immunohistochemistry Assays for Breast Cancer.

[1]  A. Jemal,et al.  Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2024, CA: a cancer journal for clinicians.

[2]  M. Salas,et al.  Potential biomarkers in breast cancer drug development: application of the biomarker qualification evidentiary framework. , 2024, Biomarkers in medicine.

[3]  Fei Liu,et al.  Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer. , 2023, The New England journal of medicine.

[4]  A. Jager,et al.  Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review , 2023, International journal of molecular sciences.

[5]  Huina Zhang,et al.  The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations , 2023, Cancers.

[6]  P. Neven,et al.  Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. , 2022, The Lancet. Oncology.

[7]  A. Gown.  The Biomarker Ki-67: Promise, Potential, and Problems in Breast Cancer , 2022, Applied immunohistochemistry & molecular morphology : AIMM.

[8]  Yihong Wang,et al.  From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine , 2022, Cancers.

[9]  Anagha P. Jadhav,et al.  Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study , 2022, Modern Pathology.

[10]  P. Fasching,et al.  Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Ellis,et al.  Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group , 2020, Journal of the National Cancer Institute.

[12]  M. Dowsett,et al.  UK NEQAS ICC & ISH Ki-67 Data Reveal Differences in Performance of Primary Antibody Clones , 2020, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  R. Røge,et al.  Ki-67 Proliferation Index in Breast Cancer as a Function of Assessment Method: A NordiQC Experience. , 2020, Applied immunohistochemistry & molecular morphology : AIMM.

[14]  Tomoharu Sugie,et al.  Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration , 2019, Histopathology.

[15]  Roger Pearce,et al.  An Image Analysis Solution For Quantification and Determination of Immunohistochemistry Staining Reproducibility , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[16]  Jennifer Won,et al.  Diagnostic Accuracy in Fit-for-Purpose PD-L1 Testing , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[17]  Steven A Bogen,et al.  A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[18]  S. Leung,et al.  Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study , 2018, Laboratory Investigation.

[19]  F. B. Sørensen,et al.  Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer , 2018, Acta oncologica.

[20]  J. Palmer,et al.  Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods , 2017, American journal of clinical pathology.

[21]  M. Salido,et al.  Heterogeneity of Tumor and Immune Cell PD‐L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples , 2017, Clinical lung cancer.

[22]  A. Mills,et al.  PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors , 2017, The American journal of surgical pathology.

[23]  Keith Miller,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics. , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[24]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[25]  R. Shui,et al.  A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer , 2016, PloS one.

[26]  Prarthana Shrestha,et al.  A quantitative approach to evaluate image quality of whole slide imaging scanners , 2016, Journal of pathology informatics.

[27]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I. Ellis,et al.  A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue , 2014, Breast Cancer Research.

[29]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[30]  S. Singh,et al.  Ki-67 is a reliable pathological grading marker for neuroendocrine tumors , 2013, Virchows Archiv.

[31]  Holger Lange,et al.  Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue , 2012, Laboratory Investigation.

[32]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[33]  Clive R. Taylor,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1 Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers , 2017, Applied immunohistochemistry & molecular morphology : AIMM.